Cargando…

Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer

The overall goal of this study was to elucidate the role of FGFR1 induction in acquired resistance to MET and VEGFR2 inhibition by cabozantinib in prostate cancer (PCa) and leverage this understanding to improve therapy outcomes. The response to cabozantinib was examined in mice bearing patient-deri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koinis, Filippos, Corn, Paul, Parikh, Nila, Song, Jian, Vardaki, Ioulia, Mourkioti, Ioanna, Lin, Sue-Hwa, Logothetis, Christopher, Panaretakis, Theocharis, Gallick, Gary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016532/ https://www.ncbi.nlm.nih.gov/pubmed/31963871 http://dx.doi.org/10.3390/cancers12010244

Ejemplares similares

Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes
por: Vardaki, Ioulia, et al.
Publicado: (2016)

The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study
por: Dayyani, Farshid, et al.
Publicado: (2016)

Cisplatin-induced apoptosis and development of resistance are transcriptionally distinct processes
por: Panaretakis, Theocharis
Publicado: (2012)

Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling
por: Nguyen, Holly M., et al.
Publicado: (2013)

Correction: Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling
Publicado: (2014)

TBX1 Represses Vegfr2 Gene Expression and Enhances the Cardiac Fate of VEGFR2+ Cells
por: Lania, Gabriella, et al.
Publicado: (2015)

Emerging Role of YAP and the Hippo Pathway in Prostate Cancer
por: Koinis, Filippos, et al.
Publicado: (2022)

Tbx1 regulates Vegfr3 and is required for lymphatic vessel development
por: Chen, Li, et al.
Publicado: (2010)

FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?
por: Gallo, Leandro H.
Publicado: (2021)

ALK+ Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes Carry ALK Signaling Proteins and Interact with Tumor Microenvironment
por: Chioureas, Dimitrios, et al.
Publicado: (2022)

Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone
por: Pan, Tianhong, et al.
Publicado: (2021)

Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer
por: Armstrong, K, et al.
Publicado: (2011)

Current perspectives on bone metastases in castrate-resistant prostate cancer
por: Logothetis, Christopher, et al.
Publicado: (2018)

Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer
por: Schaffer, Elisabeth M, et al.
Publicado: (2021)

Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
por: Liu, Guihong, et al.
Publicado: (2021)

YAP is closely correlated with castration-resistant prostate cancer, and downregulation of YAP reduces proliferation and induces apoptosis of PC-3 cells
por: SHENG, XIA, et al.
Publicado: (2015)

Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition
por: Lee, Yu-Chen, et al.
Publicado: (2022)

Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer
por: Gerdtsson, Anna S., et al.
Publicado: (2021)

Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study
por: Koinis, Filippos, et al.
Publicado: (2023)

Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer
por: Karantanos, Theodoros, et al.
Publicado: (2016)

Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms
por: Cella, Chiara Alessandra, et al.
Publicado: (2023)

YAP1 regulates prostate cancer stem cell-like characteristics to promote castration resistant growth
por: Jiang, Ning, et al.
Publicado: (2017)

MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer
por: Li, Qiji, et al.
Publicado: (2021)

Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma
por: Park, Keon Young, et al.
Publicado: (2021)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

Muscarinic receptors promote castration resistant growth of prostate cancer through a FAK-YAP signaling axis
por: Goto, Yusuke, et al.
Publicado: (2020)

Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial
por: Leibowitz-Amit, Raya, et al.
Publicado: (2016)

Multiple pathways coordinating reprogramming of endothelial cells into osteoblasts by BMP4
por: Yu, Guoyu, et al.
Publicado: (2021)

A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer
por: Mourkioti, Ioanna, et al.
Publicado: (2023)

Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone
por: Yu, Kai-Jie, et al.
Publicado: (2017)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Lack of Genetic Interaction between Tbx18 and Tbx2/Tbx20 in Mouse Epicardial Development
por: Greulich, Franziska, et al.
Publicado: (2016)

Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
por: Subudhi, Sumit K, et al.
Publicado: (2021)

Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune-checkpoint inhibitors
por: Poon, Darren MC, et al.
Publicado: (2023)

Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions
por: Kato, Yuka, et al.
Publicado: (2018)

Involvement of the AKT Pathway in Resistance to Erlotinib and Cabozantinib in Triple-Negative Breast Cancer Cell Lines
por: Lefebvre, Cory, et al.
Publicado: (2023)

Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
por: Hussain, Arif, et al.
Publicado: (2020)

Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer()()
por: Qiao, Yuanyuan, et al.
Publicado: (2016)

Targeting molecular resistance in castration-resistant prostate cancer
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3sr2ebk0v603c8496nm81lapn4